Loading...
•
Sep 30, 2022
4DMT Q3 2022 Earnings Report
Reported third quarter 2022 financial results and provided a business update.
Key Takeaways
4D Molecular Therapeutics reported third quarter 2022 financial results. The company's cash, cash equivalents and marketable securities were $239 million as of September 30, 2022, which is expected to fund operations into the first half of 2025. Total revenue for the quarter was $0.5 million and net loss was $25.7 million.
Interim clinical trial data from 4DMT’s Phase 1/2 clinical trial of 4D-710 for the treatment of cystic fibrosis lung disease was presented at North American Cystic Fibrosis Conference on November 3, 2022
Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025
Analyses of 11 total lung biopsies and brushings (Week 4) demonstrated widespread delivery and expression of the 4D-710 CFTRΔR transgene in all samples across all three patients’ lungs.
Levels of transgene expression were in a range that was predicted to be associated with clinical benefit.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com